Intuitive Ventures

The firm leverages its parent's deep relationships with academic medical centers and practicing surgeons who use da Vinci systems globally. Investigators and clinician-researchers often surface novel technologies years before they reach traditional venture networks. Intuitive Ventures also maintains active relationships with the startup ecosystems in the Bay Area and Kendall Square in Cambridge.

No. The fund operates with an independent investment committee and does not condition investment on a commercial partnership with Intuitive Surgical. Portfolio companies can and do work with other robotic platforms. The firm's public posture, confirmed across its initial fund deployments, emphasizes venture-first decision-making.

The firm invests from Seed through Series B, with a preference for companies that have a working prototype or early clinical data. Check sizes are not publicly disclosed but are consistent with lead or active co-lead positions in rounds typically ranging from $5 million to $25 million.

Investment decisions are made by the Managing Directors — Julian Nikolchev and Oliver Keown — with oversight from an independent investment committee that draws from both Intuitive Surgical senior leadership and external venture advisors. The IC structure was designed at launch to preserve deal velocity and avoid the internal R&D review cycles that slow many corporate venture arms.

The fund operates as a financially motivated venture arm, not as an extension of Intuitive Surgical's product development group. Internal R&D focuses on next-generation robotic hardware and integrated software; Intuitive Ventures invests in external companies whose technologies complement that roadmap — such as intraoperative imaging, surgical AI, and new intervention paradigms — without pulling them inside the parent company.

The firm structures its initial fund commitment to reserve capital for follow-on investments in portfolio companies that meet clinical and commercial milestones. As an early-stage-focused CVC, maintaining pro-rata in subsequent financings is central to its value-creation model, though specific reserve ratios are not publicly disclosed.

The firm has not publicly published a formal exclusion list, but its investment activity to date shows no exposure to biopharma, diagnostics, or pure-play health insurance technology. The focus remains tightly centered on procedural innovation: robotic devices, surgical software, and care-delivery models that operate in and around the operating room.